⌘K
Loading ticker…
CRISPR Therapeutics AG · Healthcare · Pharmaceutical Products
As of 2026-06-26, CRISPR Therapeutics AG (CRSP) has a 3-month relative strength percentile of 66 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 1.99×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
66 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CRSP is in a stage 1 base, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 4.1% / -1.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
CRSP appears in 1 ETF as of Mar 2026: VXF at 0.06% weight, $51M notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.06% | $51M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRSP Jan avg: 6.75% median: 3.11% win: 75% σ: 13.21% n: 4 2022-04-12 → 2026-05-29 | CRSP Feb avg: 14.11% median: 12.99% win: 75% σ: 16.36% n: 4 2022-04-12 → 2026-05-29 | CRSP Mar avg: -17.70% median: -19.98% win: 0% σ: 6.42% n: 4 2022-04-12 → 2026-05-29 | CRSP Apr avg: -1.93% median: 8.20% win: 60% σ: 17.33% n: 5 2022-04-12 → 2026-05-29 | CRSP May avg: 10.09% median: 7.34% win: 80% σ: 14.37% n: 5 2022-04-12 → 2026-05-29 | CRSP Jun avg: 6.72% median: 2.59% win: 75% σ: 19.60% n: 4 2022-04-12 → 2026-05-29 (current) | CRSP Jul avg: 11.82% median: 10.87% win: 100% σ: 9.60% n: 4 2022-04-12 → 2026-05-29 | CRSP Aug avg: -12.64% median: -12.99% win: 0% σ: 3.63% n: 4 2022-04-12 → 2026-05-29 | CRSP Sep avg: 3.66% median: -0.58% win: 50% σ: 14.85% n: 4 2022-04-12 → 2026-05-29 | CRSP Oct avg: -9.16% median: -7.75% win: 0% σ: 9.42% n: 4 2022-04-12 → 2026-05-29 | CRSP Nov avg: 17.49% median: 7.49% win: 75% σ: 37.75% n: 4 2022-04-12 → 2026-05-29 | CRSP Dec avg: -14.25% median: -14.64% win: 0% σ: 11.95% n: 4 2022-04-12 → 2026-05-29 |